Construction of a 5-methylcytosine-Related Molecular Signature to Inform the Prognosis and Immunotherapy of Lung Squamous Cell Carcinoma

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics. CA Cancer J Clin. 2022;2022:72:7–33.
   Google Scholar
• Wu F, Wang L, Zhou C. Lung cancer in China: current and prospect. Curr Opin Oncol. 2021;33(1):40–46.
   PubMed Web of Science ®Google Scholar
• Wahbah M, Boroumand N, Castro C, et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007;11(2):89–96.
   PubMed Web of Science ®Google Scholar
• Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38:23–38.
   PubMed Web of Science ®Google Scholar
• Fouad MA, Salem SE, Hussein MM, et al. Impact of Global DNA Methylation in treatment outcome of colorectal cancer patients. Front Pharmacol. 2018;9:1173.
   PubMed Web of Science ®Google Scholar
• Cui Y, Li F, Xie Q, et al. YBX1 mediates autophagy by targeting p110β and decreasing the sensitivity to cisplatin in NSCLC. Cell Death Dis. 2020;11:476.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028.
   PubMed Web of Science ®Google Scholar
• Reck M, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: checkMate 9LA 2-year update. ESMO Open. 2021;6:100273.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Liu T, Guo L, Liu G, et al. Molecular characterization of the clinical and tumor immune microenvironment signature of 5-methylcytosine-related regulators in non-small cell lung cancer. Front Cell Dev Biol. 2021;9:779367.
   PubMed Web of Science ®Google Scholar
• Hu J, Othmane B, Yu A, et al. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. BMC Med. 2021;19:289.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.
   PubMed Web of Science ®Google Scholar
• Wagner GP, Kin K, Lynch VJ. Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci. 2012;131:281–285.
   PubMed Web of Science ®Google Scholar
• Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8:118–127.
   PubMed Web of Science ®Google Scholar
• Chen YT, Shen JY, Chen DP, et al. Identification of cross-talk between m(6)A and 5mC regulators associated with onco-immunogenic features and prognosis across 33 cancer types. J Hematol Oncol. 2020;13:22.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet. 2017;18:517–534.
   PubMed Web of Science ®Google Scholar
• Schübeler D. Function and information content of DNA methylation. Nature. 2015;517:321–326.
   PubMed Web of Science ®Google Scholar
• Ginder GD, Williams DC Jr. Readers of DNA methylation, the MBD family as potential therapeutic targets. Pharmacol Ther. 2018;184:98–111.
   PubMed Web of Science ®Google Scholar
• Kursa MB, Rudnicki WR. Feature selection with the boruta package. J Stat Softw. 2010;36: 1-13-13.
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262–272.
   PubMed Web of Science ®Google Scholar
• Zhang X, Shi M, Chen T, et al. Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy. Mol Ther Nucleic Acids. 2020;22:298–309.
   PubMedGoogle Scholar
• Liao Y, He D, Wen F. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy. Immunogenetics. 2021;73:369–380.
   PubMed Web of Science ®Google Scholar
• Binatti A, Bresolin S, Bortoluzzi S, et al. iWhale: a computational pipeline based on Docker and SCons for detection and annotation of somatic variants in cancer WES data. In: Brief bioinform. 2021;22:bbaa065.
   Google Scholar
• Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747–1756.
   PubMed Web of Science ®Google Scholar
• Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28:3044–3050.
   PubMed Web of Science ®Google Scholar
• Kim JY, Choi JK, Jung H. Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer. Clin Epigenetics. 2020;12:119.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma. Cell. 2016;165:35–44.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–7259.
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
   PubMed Web of Science ®Google Scholar
• Signer RA, Magee JA, Salic A, et al. Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature. 2014;509:49–54.
   PubMed Web of Science ®Google Scholar
• Blanco S, Bandiera R, Popis M, et al. Stem cell function and stress response are controlled by protein synthesis. Nature. 2016;534:335–340.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–2104.
   PubMed Web of Science ®Google Scholar
• Wang Z, Luo Z, Zhou L, et al. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway. Cancer Sci. 2015;106:1303–1312.
   PubMed Web of Science ®Google Scholar
• Gao SH, Wang GZ, Wang LP, et al. Mutations and clinical significance of calcium voltage-gated channel subunit alpha 1E (CACNA1E) in non-small cell lung cancer. Cell Calcium. 2022;102:102527
   PubMed Web of Science ®Google Scholar